Ipilimumab
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Exelixis
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT04717154CT.gov Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT04388852CT.gov DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT05655715CT.gov Checkpoint Inhibitors and SBRT for MCRPC | — | Completed | — | — | — |
NCT02703623CT.gov Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT01832870CT.gov Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Exelixis | P2 | B · 59 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →